Survival analyses suggested that high expression of SLC2A1-DT was linked with shorter overall survival (OS), disease-free interval (DFI), disease-specific survival (DSS), and progression-free interval (PFI) of HCC patients (Fig. 1F). The gene discussed is SLC2A1; the disease is hepatocellular carcinoma.